Compare Apartment Investment and Management Co (AIV) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Gilead Sciences, Inc. — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 447.5× Apartment Investment and Management Co's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.
| AIV | GILD | |
|---|---|---|
Market Cap | $376.16M | $168.35B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $155.80 |
52-Week Low | $2.59 | $110.56 |
Enterprise Value | $738.32M | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.605, down 0.57% on the day, with a bearish technical outlook showing 13 sell signals on moving averages. The stock presents a mixed fundamental picture with a strong 400% net income margin and 228% ROE for 2025, though revenue declined to $138M from $209M in 2024. Recent earnings show volatility with two beats and two misses in the last four quarters. The company announced a $1.30 dividend for H1-2026, payable in June 2026.
AIV offers value with a P/B ratio of 0.76 and positive cash flow generation, but faces challenges from declining revenue and inconsistent earnings performance. The bearish technical setup and mixed analyst sentiment (33% buy, 67% hold) suggest cautious optimism. Key risks include execution volatility and real estate sector headwinds, while the dividend provides income support.
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
